Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma

Giuseppe Basile(Vita-Salute San Raffaele University), Umberto Capitanio(Vita-Salute San Raffaele University), Alexandre Mottrie(Instituut voor Landbouw en Visserijonderzoek), Alessandro Larcher(IRCCS Ospedale San Raffaele), Roberto Bertini, Alberto Martini(The University of Texas MD Anderson Cancer Center), Andrea Salonia(Vita-Salute San Raffaele University), Chiara Re(Vita-Salute San Raffaele University), Daniele Cignoli(Istituti di Ricovero e Cura a Carattere Scientifico), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Montorsi(Vita-Salute San Raffaele University), Giuseppe Fallara(Istituti di Ricovero e Cura a Carattere Scientifico), Giuseppe Rosiello(Vita-Salute San Raffaele University), Andrea Necchi(Vita-Salute San Raffaele University), Pierre I. Karakiewicz(Université de Montréal), Alberto Briganti(Vita-Salute San Raffaele University), Zhe Tian(Tianjin University)
Urologic Oncology Seminars and Original Investigations
May 31, 2022
10.1016/j.urolonc.2022.05.012
Cited by 7

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656